Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is committed to the work we do in collaboration with @USDA_APHIS and #FSIS and our shared effort to advance public health through nutrition and food safety, and FDA will continue to advance these goals as part of our food center’s core mission https: QT @SecAzar: I was delighted to meet with @SecretarySonny today to discuss our areas of collaboration around food safety and the… https://t.co/OOSIijGMQg)
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is committed to the food safety work we do in collaboration with @USDA_APHIS and #FSIS and our shared effort to advance public health through nutrition and food safety and FDA will continue to advance these goals through our food center’s core missio QT @SecAzar: I was delighted to meet with @SecretarySonny today to discuss our areas of collaboration around food safety and the… https://t.co/OOSIijGMQg)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SecAzar: I was delighted to meet with @SecretarySonny today to discuss our areas of collaboration around food safety and the… https://t.co/OOSIijGMQg
SteveFDA (R-D.C.)
@SGottliebFDA
My statement on #FDA’s Online Opioid Summit. It was clear everyone in the room has a shared desire to prevent bad actors from selling illicit drugs online and a commitment to doing their part to combat the opioid epidemic. https://t.co/TtkuIQniGk
SteveFDA (R-D.C.)
@SGottliebFDA
Yesterday, #FDA hosted a variety of internet stakeholders to discuss the illegal sale of opioids online. Today I’m providing a recap of that meeting and next steps. Our work with internet stakeholders to combat this problem is just beginning. https://t.co
SteveFDA (R-D.C.)
@SGottliebFDA
Medication-assisted treatment provides safe/controlled levels of medication to treat opioid use disorder. At proper doses, research has shown that MAT has no adverse effects on a person’s intelligence, mental capability, physical functioning or employabil
SteveFDA (R-D.C.)
@SGottliebFDA
By sequencing the DNA of pathogens, WGS reveals markers like genetic fingerprint and antimicrobial resistance, and offers clues about geographic source. This helps scientists respond more effectively to food contamination, allowing faster recalls and prev
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RAPSorg: Continuous Glucose Monitors: @US_FDA Grants Pediatric Indication to @Medtronic Device, Approves Senseonics System |… https://t.co/JgjxeegLaX
SteveFDA (R-D.C.)
@SGottliebFDA
We’re evaluating the comments we received and will advance a new approach to how we treat maple syrup and honey under the new nutrition facts label. We’ve heard the concerns, and we’re developing a new approach that takes measure of them https://t.co/OfsT
SteveFDA (R-D.C.)
@SGottliebFDA
RT @fdalawblog: Like Ma Bell, I’ve Got the Ill Communications: Final Guidances Issued - https://t.co/KypjVHg2Fc
SteveFDA (R-D.C.)
@SGottliebFDA
The collected impact of these policies has helped improve the efficiency of drug development for medicines targeted to unmet medical needs. This is seen across many serious diseases; benefiting patients through earlier access to safe, effective treatments
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA, working with FBI, Postal Inspectors, play an important role in protecting integrity of medical products. We encourages innovation, but we’re committed to taking action against those who defraud consumers about medical product safety and effectivenes
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
In the setting of the opioid epidemic, it’s part of #FDA’s public health mandate to promote the appropriate use of medicine, including MAT to treat opioid use disorder, and take a more active role to address the misunderstanding and stigma around medical
SteveFDA (R-D.C.)
@SGottliebFDA
The decision to disband that single adcom of the dozens and dozens of advisory committees we maintain was made by FDA career leadership for sound scientific and programmatic reasons; and FDA will always promote science based decision making and seek the c
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
Owing to effectiveness of new drugs and the desire of patients to cross over to promising therapies; leaving dying patients on comparator arms for long periods, just to measure survival stats, can be hard. So we're trying to modernize clinical trial desig
SteveFDA (R-D.C.)
@SGottliebFDA
Our proposed modernization of FDA’s Office of New Drugs will help make sure drug review divisions are more therapeutically focused; to promote efficiency and provide greater scientific collaboration with academic partners, innovators, and patient groups.
SteveFDA (R-D.C.)
@SGottliebFDA
FDA’s draft guidance today encourages companies to use innovative manufacturing tech and processes, making it easier for them to manage post-approval changes across different global markets by reducing unnecessary regulatory burdens and costs. https://t.c